{"title":"新型室内滞留喷洒产品 VECTRON™ T500（broflanilide）对抗性除虫菊酯类疟疾病媒的持久滞留功效及其在布基纳法索社区试验中的接受程度。","authors":"Aristide Sawdetuo Hien, Koama Bayili, Samina Maiga, Welbeck Oumbouke, Jean Birba, Dieudonné Diloma Soma, Adissa Ya Ouattara, Delphine Ouissamien Karama, Marlize Coleman, Janneke Snetselaar, Graham Small, Shinya Niimi, Kawase Ayumi, Sidzabda Kompaoré, Katsutoshi Tsuchiya, Roch Kounbobr Dabiré, Abdoulaye Diabaté","doi":"10.1186/s13071-024-06577-y","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The WHO Global Malaria Programme advocates for a comprehensive, strategic approach to managing insecticide resistance, highlighting the importance of using multiple insecticides with different modes of action through rotations and combinations. To slow the spread of resistance, it is essential to develop and evaluate new formulations that feature unique modes of action and extended residual effects. Addressing this need, Mitsui Chemicals Crop & Life Solutions, Inc., developed VECTRON™ T500, a new indoor residual spraying (IRS) formulation using broflanilide, applied at a dosage of 100 mg AI/m<sup>2</sup>. This formulation was tested in a Phase III community trial, alongside Actellic<sup>®</sup> 300CS, a commonly used IRS product containing pirimiphos-methyl, applied at the recommended dosage of 1000 mg AI/m<sup>2</sup>.</p><p><strong>Methods: </strong>Monthly WHO wall cone bioassays were performed to assess the efficacy of the interventions using three mosquito strains: the laboratory-bred, insecticide-susceptible Anopheles gambiae s.s. Kisumu strain, the insecticide-resistant Anopheles coluzzii VKPer strain, and wild Anopheles gambiae s.l. mosquitoes from the Vallée du Kou, where the study was conducted. Vector surveillance was carried out to compare the results between sites treated with VECTRON™ T500, Actellic<sup>®</sup> 300CS, and an untreated control site. In addition, any reported adverse effects were closely monitored to evaluate the community's acceptance of VECTRON<sup>™</sup> T500.</p><p><strong>Results: </strong>VECTRON™ T500 consistently achieved 100% mortality across all wall types for both susceptible and resistant mosquito strains over the 12-month period. In comparison, Actellic<sup>®</sup> 300CS induced < 80% mortality for both strains, irrespective of the wall substrate. When assessing delayed mortality in An. gambiae s.l. mosquitoes collected from sites treated with Actellic<sup>®</sup> 300CS (VK1) and VECTRON™ T500 (VK3), a statistically significant difference was noted after a 72-h holding period compared to the control site (RR = 0.51, CI95% = [0.31-0.6], P = 0.0026). Additionally, no adverse events were reported in households sprayed with VECTRON™ T500.</p><p><strong>Conclusions: </strong>The residual efficacy of VECTRON<sup>™</sup> T500 extended for 12 months post-spraying, effectively covering the full malaria transmission season while maintaining high mortality rates in pyrethroid-resistant malaria vectors. VECTRON<sup>™</sup> T500 demonstrated non-inferiority in performance compared to Actellic<sup>®</sup> 300CS, the standard reference product. This new IRS formulation has the potential to play a crucial role in managing insecticide resistance by being integrated into a rotational strategy alongside other IRS products containing insecticides with different modes of action.</p>","PeriodicalId":19793,"journal":{"name":"Parasites & Vectors","volume":"17 1","pages":"484"},"PeriodicalIF":3.0000,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11585240/pdf/","citationCount":"0","resultStr":"{\"title\":\"Long-lasting residual efficacy of a new indoor residual spraying product, VECTRON<sup>™</sup> T500 (broflanilide), against pyrethroid-resistant malaria vectors and its acceptance in a community trial in Burkina Faso.\",\"authors\":\"Aristide Sawdetuo Hien, Koama Bayili, Samina Maiga, Welbeck Oumbouke, Jean Birba, Dieudonné Diloma Soma, Adissa Ya Ouattara, Delphine Ouissamien Karama, Marlize Coleman, Janneke Snetselaar, Graham Small, Shinya Niimi, Kawase Ayumi, Sidzabda Kompaoré, Katsutoshi Tsuchiya, Roch Kounbobr Dabiré, Abdoulaye Diabaté\",\"doi\":\"10.1186/s13071-024-06577-y\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>The WHO Global Malaria Programme advocates for a comprehensive, strategic approach to managing insecticide resistance, highlighting the importance of using multiple insecticides with different modes of action through rotations and combinations. To slow the spread of resistance, it is essential to develop and evaluate new formulations that feature unique modes of action and extended residual effects. Addressing this need, Mitsui Chemicals Crop & Life Solutions, Inc., developed VECTRON™ T500, a new indoor residual spraying (IRS) formulation using broflanilide, applied at a dosage of 100 mg AI/m<sup>2</sup>. This formulation was tested in a Phase III community trial, alongside Actellic<sup>®</sup> 300CS, a commonly used IRS product containing pirimiphos-methyl, applied at the recommended dosage of 1000 mg AI/m<sup>2</sup>.</p><p><strong>Methods: </strong>Monthly WHO wall cone bioassays were performed to assess the efficacy of the interventions using three mosquito strains: the laboratory-bred, insecticide-susceptible Anopheles gambiae s.s. Kisumu strain, the insecticide-resistant Anopheles coluzzii VKPer strain, and wild Anopheles gambiae s.l. mosquitoes from the Vallée du Kou, where the study was conducted. Vector surveillance was carried out to compare the results between sites treated with VECTRON™ T500, Actellic<sup>®</sup> 300CS, and an untreated control site. In addition, any reported adverse effects were closely monitored to evaluate the community's acceptance of VECTRON<sup>™</sup> T500.</p><p><strong>Results: </strong>VECTRON™ T500 consistently achieved 100% mortality across all wall types for both susceptible and resistant mosquito strains over the 12-month period. In comparison, Actellic<sup>®</sup> 300CS induced < 80% mortality for both strains, irrespective of the wall substrate. When assessing delayed mortality in An. gambiae s.l. mosquitoes collected from sites treated with Actellic<sup>®</sup> 300CS (VK1) and VECTRON™ T500 (VK3), a statistically significant difference was noted after a 72-h holding period compared to the control site (RR = 0.51, CI95% = [0.31-0.6], P = 0.0026). Additionally, no adverse events were reported in households sprayed with VECTRON™ T500.</p><p><strong>Conclusions: </strong>The residual efficacy of VECTRON<sup>™</sup> T500 extended for 12 months post-spraying, effectively covering the full malaria transmission season while maintaining high mortality rates in pyrethroid-resistant malaria vectors. VECTRON<sup>™</sup> T500 demonstrated non-inferiority in performance compared to Actellic<sup>®</sup> 300CS, the standard reference product. This new IRS formulation has the potential to play a crucial role in managing insecticide resistance by being integrated into a rotational strategy alongside other IRS products containing insecticides with different modes of action.</p>\",\"PeriodicalId\":19793,\"journal\":{\"name\":\"Parasites & Vectors\",\"volume\":\"17 1\",\"pages\":\"484\"},\"PeriodicalIF\":3.0000,\"publicationDate\":\"2024-11-23\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11585240/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Parasites & Vectors\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s13071-024-06577-y\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PARASITOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Parasites & Vectors","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13071-024-06577-y","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PARASITOLOGY","Score":null,"Total":0}
Long-lasting residual efficacy of a new indoor residual spraying product, VECTRON™ T500 (broflanilide), against pyrethroid-resistant malaria vectors and its acceptance in a community trial in Burkina Faso.
Background: The WHO Global Malaria Programme advocates for a comprehensive, strategic approach to managing insecticide resistance, highlighting the importance of using multiple insecticides with different modes of action through rotations and combinations. To slow the spread of resistance, it is essential to develop and evaluate new formulations that feature unique modes of action and extended residual effects. Addressing this need, Mitsui Chemicals Crop & Life Solutions, Inc., developed VECTRON™ T500, a new indoor residual spraying (IRS) formulation using broflanilide, applied at a dosage of 100 mg AI/m2. This formulation was tested in a Phase III community trial, alongside Actellic® 300CS, a commonly used IRS product containing pirimiphos-methyl, applied at the recommended dosage of 1000 mg AI/m2.
Methods: Monthly WHO wall cone bioassays were performed to assess the efficacy of the interventions using three mosquito strains: the laboratory-bred, insecticide-susceptible Anopheles gambiae s.s. Kisumu strain, the insecticide-resistant Anopheles coluzzii VKPer strain, and wild Anopheles gambiae s.l. mosquitoes from the Vallée du Kou, where the study was conducted. Vector surveillance was carried out to compare the results between sites treated with VECTRON™ T500, Actellic® 300CS, and an untreated control site. In addition, any reported adverse effects were closely monitored to evaluate the community's acceptance of VECTRON™ T500.
Results: VECTRON™ T500 consistently achieved 100% mortality across all wall types for both susceptible and resistant mosquito strains over the 12-month period. In comparison, Actellic® 300CS induced < 80% mortality for both strains, irrespective of the wall substrate. When assessing delayed mortality in An. gambiae s.l. mosquitoes collected from sites treated with Actellic® 300CS (VK1) and VECTRON™ T500 (VK3), a statistically significant difference was noted after a 72-h holding period compared to the control site (RR = 0.51, CI95% = [0.31-0.6], P = 0.0026). Additionally, no adverse events were reported in households sprayed with VECTRON™ T500.
Conclusions: The residual efficacy of VECTRON™ T500 extended for 12 months post-spraying, effectively covering the full malaria transmission season while maintaining high mortality rates in pyrethroid-resistant malaria vectors. VECTRON™ T500 demonstrated non-inferiority in performance compared to Actellic® 300CS, the standard reference product. This new IRS formulation has the potential to play a crucial role in managing insecticide resistance by being integrated into a rotational strategy alongside other IRS products containing insecticides with different modes of action.
期刊介绍：
Parasites & Vectors is an open access, peer-reviewed online journal dealing with the biology of parasites, parasitic diseases, intermediate hosts, vectors and vector-borne pathogens. Manuscripts published in this journal will be available to all worldwide, with no barriers to access, immediately following acceptance. However, authors retain the copyright of their material and may use it, or distribute it, as they wish.
Manuscripts on all aspects of the basic and applied biology of parasites, intermediate hosts, vectors and vector-borne pathogens will be considered. In addition to the traditional and well-established areas of science in these fields, we also aim to provide a vehicle for publication of the rapidly developing resources and technology in parasite, intermediate host and vector genomics and their impacts on biological research. We are able to publish large datasets and extensive results, frequently associated with genomic and post-genomic technologies, which are not readily accommodated in traditional journals. Manuscripts addressing broader issues, for example economics, social sciences and global climate change in relation to parasites, vectors and disease control, are also welcomed.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
